[Edaily Reporter Kwon Oh Seok ] LabGenomics. Co., Ltd.(084650)’s stock price is surging in early trading. It appears that buying interest is surging on news that the company is accelerating efforts to strengthen its sales infrastructure in the U.S.

According to MP Doctor on the 4th, LabGenomics. Co., Ltd. is trading at 706 won as of 9:16 a.m., up 22.15% from the previous trading day.
Earlier today, LabGenomics. Co., Ltd. issued a press release stating, “Last month, we held a ‘National Sales Meeting’ at our laboratory in New Jersey, attended by sales personnel from across the United States.”
This sales meeting was organized as a forum for sales representatives from various fields to share sales case studies and expertise in key testing areas, including cancer diagnostic tests, digital pathology-based tests, dermatopathology tests, and “Lumipulse,” a blood-based Alzheimer’s disease diagnostic test.
In particular, the company explained that this event was significant as it marked the first company-wide sales meeting held since the recent integration of two Clinical Laboratory Improvement Amendments (CLIA)-certified labs under the single “LabGenomics. Co., Ltd.” brand. Sales personnel active in 27 U.S. states gathered in one place to share field experiences and strengthen collaboration within the unified organization.
LabGenomics. Co., Ltd. has doubled the size of its sales organization and appointed Tim Murray—who has over 20 years of experience in the U.S. diagnostic testing sales sector—as Executive Vice President of Sales, thereby reorganizing its sales structure by region and specialty. Executive Vice President Tim Murray oversees the general diagnostic and cancer diagnostic sales operations of the U.S. subsidiaries and is leading the development of sales strategies and market expansion across the entire United States.
To expand its U.S. diagnostic testing business, LabGenomics. Co., Ltd. plans to extend the sales reach of its general and cancer diagnostic tests—which were previously limited to certain regions—to the entire United States. The company also intends to promote cross-selling among sales teams and expand its test menu offerings targeting large hospitals and clinics.